The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic Chemotherapy.

Detalles Bibliográficos
Publicado en:Oncology (08909091) Vol. 27; no. 10; pp. 1028 - 1030
Autores principales: MALKHASYAN, KAREN, DESHPANDE, HARI A., ADENIRAN, ADEBOWALE J., COLBERG, JOHN W., PETRYLAK, DANIEL P.
Formato: case study pictorial tables/charts Journal Article
Publicado: MJH Life Sciences Oct2013
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=91745009&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 91745009
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        08909091
        YYT
      jtl: Oncology (08909091)
      issn: 08909091
      maglogo: N
    pubinfo:
      dt: Oct2013
      vid: 27
      iid: 10
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        91745009
        91745009
        107934503
        91745009
      ppf: 1028
      ppct: 2
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic Chemotherapy.
      aug:
        au:
          MALKHASYAN, KAREN
          DESHPANDE, HARI A.
          ADENIRAN, ADEBOWALE J.
          COLBERG, JOHN W.
          PETRYLAK, DANIEL P.
        affil: Yale-New Haven Hospital, New Haven, Connecticut
      sug:
        subj:
          Gonadotropins, Chorionic Blood
          Bladder Neoplasms Radiography
          Neoplasm Metastasis Radiography
          Neoplasm Metastasis Therapy
          Lung Neoplasms Radiography
          Disease Progression
          Middle Age
          Female
          Bladder Neoplasms Surgery
          Neoplasm Recurrence, Local
          Tomography, Emission-Computed
          Lung Neoplasms Therapy
          Chemotherapy, Adjuvant
          Treatment Outcomes
          Middle Aged: 45-64 years
          Female
      pubtype: Academic Journal
      doctype:
        case study
        pictorial
        tables/charts
        Journal Article
      ougenre: Unknown
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N